Dose2Value Clinical

About Dose2Value Clinical

Dose2Value (D2V) Clinical operates as a full-service global Contract Research Organization (CRO) specializing in early-phase clinical trials for the biopharmaceutical sector. Launched in April 2023, the company was established by a team of seasoned professionals with extensive backgrounds in the pharmaceutical industry and at the U.S. Food and Drug Administration (FDA). The founding leadership team includes CEO Amanda Fu and Chief Medical Officer Vijay Reddy, both formerly of MedImmune, alongside President Walter Cao, a former senior pharmacology reviewer at the FDA, and Chief Development Officer Jill Loftiss, also from MedImmune.

The company's core business is providing end-to-end clinical development services to biotech companies, primarily in the United States and China, with a strategic focus on expediting drug signal detection and program advancement. D2V Clinical's operational sweet spot lies in early-phase oncology, hematology, and rare disease studies, where specialized expertise is critical. For its clients, which are often smaller drug developers lacking extensive in-house resources, D2V Clinical offers a comprehensive suite of services. These include dose optimization strategy, translational medicine, clinical pharmacology, study protocol design, and interaction with regulatory bodies like the FDA. The business model hinges on creating value for sponsors by navigating the complexities of early-stage trials, aiming to identify the right dose for the right patient population as efficiently as possible to prevent costly late-stage failures.

D2V Clinical's service portfolio is designed to manage critical trial milestones, covering first-in-human (FIH) studies, dose-finding and optimization studies (SAD/MAD), and various pharmacokinetic/pharmacodynamic (PK/PD) assessments. The firm leverages a robust network of principal investigators and access to EMR data to accelerate patient enrollment. In 2024, the company announced an expansion of its therapeutic focus to include ophthalmology, metabolic diseases, cardiology, women's healthcare, autoimmune diseases, and dermatology, alongside enhancing its clinical trial site network and integrating digital health tools to improve trial efficiency and patient engagement.